NCT00790595 - Clinical Study of SU011248 in Subjects With High Risk Prostate Cancer Who Have Elected to Undergo Radical Prostatectomy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

July 31, 2009

Conditions

Prostate Cancer

Interventions

DRUG

SU011248

5 Subjects will receive 50.0 mg/d of the study drug for 2 weeks.

DRUG

SU011248

5 Subjects will receive 50.0 mg/d of the study drug for 4 weeks.

DRUG

SU011248

5 Subjects will receive 50.0 mg/d of the study drug for 1 week.

DRUG

SU011248

5 Subjects will receive 37.5 mg/d of the study drug for 1 week.

DRUG

SU011248

5 Subjects will receive 37.5 mg/d of the study drug for 2 weeks.

Trial Locations (1)

University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles